RecruitingPhase 3NCT06476184
Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
Studying Malignant epithelial tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ARCAGY/ GINECO GROUP
- Principal Investigator
- Benoit YOUHCL - Centre Hospitalier Lyon Sud
- Intervention
- Carboplatin(drug)
- Enrollment
- 250 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2024 – 2028
Study locations (30)
- ICO Paul Papin, Angers, France
- CH d'Avignon, Avignon, France
- Sainte-Catherine Institut du Cancer Avignon-Provence, Avignon, France
- Hôpital de la Côte Basque, Bayonne, France
- CHRU Besançon - Hôpital Jean Minjoz, Besançon, France
- Institut Bergonié, Bordeaux, France
- CHU de BREST - Hôpital Cavale Blanche, Brest, France
- Centre François Baclesse, Caen, France
- Centre d'Oncologie et de Radiothérapie 37 (ROC37), Chambray-lès-Tours, France
- Centre Hospitalier de Cholet, Cholet, France
- Centre Jean Perrin, Clermont-Ferrand, France
- Centre Hospitalier Alpes Leman, Contamine-sur-Arve, France
- Centre Hospitalier Intercommunal de Créteil, Créteil, France
- Centre Georges François Leclerc, Dijon, France
- CHU de Dijon, Dijon, France
- +15 more locations on ClinicalTrials.gov
Collaborators
Horizon 2020 - European Commission
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06476184 on ClinicalTrials.govOther trials for Malignant epithelial tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07508306Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP/UO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical MorbidityFaculty of Medicine of Tunis
- RECRUITINGPHASE1NCT07524322Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid TumorsRegor Pharmaceuticals Inc.
- RECRUITINGPHASE1NCT06366490Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian CancerPhotonPharma, Inc.
- RECRUITINGPHASE1NCT07402915Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube CancerAstraZeneca
- RECRUITINGNANCT07280312Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal LesionsMayo Clinic
- RECRUITINGPHASE2NCT07158021Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS TrialUniversity of Michigan Rogel Cancer Center
- RECRUITINGPHASE2NCT06971744Autophagy Maintenance (AUTOMAIN)Medical University of South Carolina
- RECRUITINGPHASE3NCT06963268Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II)Instituto de Investigacion Sanitaria La Fe